The scoop: This was Astute's third round. The diagnostics company has big plans to start commercialization of its first product. And there are other diagnostic tests in the pipeline that will need further development, reports FierceMedicalDevices. The life sciences company intends to roll out a lineup of tests hospitals will be able to use to assess a slate of symptoms, like abdominal pain and kidney injury. Investors had already put in close to $33 million when the Series C came together.